CIM LLC’s Supernus Pharmaceuticals SUPN Stock Holding History

CIM LLC’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-3,465	Closed	-$207K	–	121
2018 Q2	$207K	Buy	+3,465	New	+$180K	0.07%	105
2017 Q4	–	Sell	-12,210	Closed	-$488K	–	102
2017 Q3	$488K	Buy	+12,210	New	+$528K	0.2%	54

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

CIM LLC's SUPN Position: Q3 2018 in Review

CIM LLC sold out of Supernus Pharmaceuticals (SUPN) in Q3 2018, closing a stake of 3,465 shares — an estimated $207K sold.

CIM LLC first reported a position in SUPN in Q3 2017 and held it in 2 quarters. The position peaked at $488K in Q3 2017. 288 funds tracked by Wall St. Rank hold SUPN as of Q3 2018.

CIM LLC reported no remaining Supernus Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
CIM LLC sold 3,465 Supernus Pharmaceuticals shares in Q3 2018, an estimated $207K.
CIM LLC first reported a position in Supernus Pharmaceuticals in Q3 2017 and held it in 2 quarters.
CIM LLC's Supernus Pharmaceuticals position peaked at $488K in Q3 2017.
288 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2018.

Based on CIM LLC's 13F filing for Q3 2018, filed 29 Oct 2018.